Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 244 of the 254 references it cites were found in a registry or an index; 39 of the 166 sources its claims cite were checked for support.

Novel therapeutic targets for cholestatic and fatty liver disease

Open access

Abstract

Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key pathophysiological mechanisms which can be targeted by novel therapeutic concepts that are currently developed for both areas. Nuclear receptors (NRs) are ligand-activated transcriptional regulators of key metabolic processes including hepatic lipid and glucose metabolism, energy expenditure and bile acid (BA) homoeostasis, as well as inflammation, fibrosis and cellular proliferation. Dysregulation of these processes contributes to the pathogenesis and progression of cholestatic as well as fatty liver disease, placing NRs at the forefront of novel therapeutic approaches. This includes BA and fatty acid activated NRs such as farnesoid-X receptor (FXR) and peroxisome proliferator-activated receptors, respectively, for which high affinity therapeutic ligands targeting specific or multiple isoforms have been developed. Moreover, novel liver-specific ligands for thyroid hormone receptor beta 1 complete the spectrum of currently available NR-targeted drugs. Apart from FXR ligands, BA signalling can be targeted by mimetics of FXR-activated fibroblast growth factor 19, modulation of their enterohepatic circulation through uptake inhibitors in hepatocytes and enterocytes, as well as novel BA derivatives undergoing cholehepatic shunting (instead of enterohepatic circulation). Other therapeutic approaches more directly target inflammation and/or fibrosis as critical events of disease progression. Combination strategies synergistically targeting metabolic disturbances, inflammation and fibrosis may be ultimately necessary for successful treatment of these complex and multifactorial disorders.

Overview

CoChat Summary

TL;DR

This review argues that cholestatic and non-alcoholic fatty liver disease share key pathophysiological mechanisms and that nuclear receptors and bile acid signalling are leading therapeutic targets. It summarizes phase 2/3 trial data for FXR, PPAR, FGF19/21, THR-β1, norUDCA, CCR2/5, and LOXL2-directed agents, concluding that combination strategies may ultimately be necessary.

Key findings

  • Cholestasis and NAFLD/NASH converge on substrate overload, cell stress, inflammation, and fibrosis; nuclear receptors are broadly expressed in hepatocytes, cholangiocytes, hepatic stellate cells, and immune cells, making them attractive targets.
  • FXR/BA-directed therapies show mixed results: in PBC, obeticholic acid improved biochemical markers and was conditionally approved as second-line therapy; in NASH, FLINT reported improved NAFLD activity score but NASH resolution of 22% vs 13% with placebo, while fibrosis improved in 35% vs 19%; REGENERATE interim analysis showed fibrosis improvement >1 stage in 23% vs 12% with placebo but no significant NASH improvement (12% vs 8%).
  • PPAR and THR-β1 ligands also show signals: bezafibrate produced complete biochemical response in 31% of PBC patients with incomplete UDCA response vs 0% on placebo, with ALP normalisation in 67%; pioglitazone improved transaminases, steatosis, and inflammation but not fibrosis or NASH in PIVENS; resmetirom reduced hepatic fat and improved histological NAS in phase 2 NASH.
  • Other approaches include norUDCA, which improved ALP in phase 2 PSC and reduced ALT in phase 2a NAFLD, while cenicriviroc showed no significant antifibrotic effect at 2 years and the AURORA phase 3 trial was terminated early for lack of efficacy; simtuzumab failed to improve fibrosis in NASH or PSC.

Methods

  • Narrative review synthesizing mechanistic literature and clinical trial data across cholestatic liver diseases and NAFLD/NASH.
  • Table 1 compiles key clinical trials of steroidal and non-steroidal FXR agonists, FGF19 mimetics, PPAR agonists, FGF21 mimetics, THR-β1 agonists, norUDCA, CCR2/CCR5 antagonists, and LOXL2 inhibitors.
  • No systematic search, meta-analysis, or primary data collection is reported.

Limitations

  • The paper states that long-term efficacy, tolerability, and safety of novel therapies still need evaluation, and that benefit on “hard” clinical endpoints remains to be demonstrated for OCA in PBC.
  • The paper notes challenges such as high malignancy risk in PSC and the need for innovative trial designs such as basket trials.
  • Evident from the text: this is a narrative review with selected trial coverage, including interim and ongoing study results, and no quantitative synthesis; later trials published after 2022 are not included.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2021-324305

Cites

244 of 244 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Failed metabolic homoeostasis results in sublethal cell stress, inflammation and fibrosis. In both non-alcoholic fatty liver disease and cholestasis, inadequate metabolic adaptation to substrate overload results in sublethal cell stress or even cell death with release of mediators (eg, cytokines, chemokines, microRNAs), in part as cargo of extracellular vesicles, driving inflammation and fibrosis. The ideal therapeutic strategy would be expected to impact on several if not all critical steps involved in the initiation and progression of liver diseases. Combination strategies synergistically targeting metabolic disturbances, inflammation and fibrosis may be ultimately necessary for successful treatment of complex cholestatic and metabolic liver diseases.
Figure 1 Failed metabolic homoeostasis results in sublethal cell stress, inflammation and fibrosis. In both non-alcoholic fatty liver disease and cholestasis, inadequate metabolic adaptation to substrate overload results in sublethal cell stress or even cell death with release of mediators (eg, cytokines, chemokines, microRNAs), in part as cargo of extracellular vesicles, driving inflammation and fibrosis. The ideal therapeutic strategy would be expected to impact on several if not all critical steps involved in the initiation and progression of liver diseases. Combination strategies synergistically targeting metabolic disturbances, inflammation and fibrosis may be ultimately necessary for successful treatment of complex cholestatic and metabolic liver diseases.CC BY-NC · PubMed Central
Figure 2 Therapeutic strategies along the enterohepatic and cholehepatic bile acid (BA) circulation. After hepatic synthesis via cytochrome P450 7A1 (CYP7A1) and excretion into bile through the bile salt export pump (BSEP/ABCB11) BAs undergo an enterohepatic circulation, that is, they are reabsorbed in the ileum by apical sodium-dependent bile acid transporter (ASBT/SLC10A2) and transported back to the liver through portal blood where hepatic reuptake of conjugated BAs is mediated via sodium/taurocholate cotransporting polypeptide (NTCP/SLC10A1) and organic anion transporting polypeptides (OATPs) for unconjugated BAs (not shown). In hepatocytes, farnesoid-X receptor (FXR) induces the transcriptional repressor SHP which in turn inhibits CYP7A1 (BA synthesis) and NTCP transcription (BA uptake). FXR induces BSEP, phospholipid export pump/floppase (MDR3/ABCB4; Mdr2 in mice) and cholesterol export pump (ABCG5/8). At the basolateral membrane organic solute transporter (OSTα/OSTβ), multidrug resistance-related proteine (MRP)3 and MRP4 facilitate alternative hepatic BA pump which is also in part induced by FXR (not shown). After uptake of BAs via ASBT into enterocytes (lower panel), BA-activated FXR induces sinusoidal OSTα/OSTβ heterodimer for BA efflux into portal blood. Intestinal FXR via DIET1 induces fibroblast growth factor (FGF) 19, which circulates to the liver and binds to its receptor FGFR4, subsequently inhibiting BA synthesis. Gut microbiota deconjugate and dehydroxylate primary BAs into secondary BAs. Enterohepatic drugs acting within the gut-liver axis: (non-)steroidal FXR agonists (eg, obeticholic acid) and FGF19 mimetics. Cholehepatic drugs, such as nor-ursodeoxycholic acid (norUDCA), undergo cholehepatic shunting between hepatocytes and cholangiocytes, thereby cutting short the enterohepatic circulation. Transport blockers: ASBT inhibitors and BA sequestrants as well as NTCP inhibitors, prevent intestinal or hepatic BA reuptake. TJ, tight junction.
Figure 2 Therapeutic strategies along the enterohepatic and cholehepatic bile acid (BA) circulation. After hepatic synthesis via cytochrome P450 7A1 (CYP7A1) and excretion into bile through the bile salt export pump (BSEP/ABCB11) BAs undergo an enterohepatic circulation, that is, they are reabsorbed in the ileum by apical sodium-dependent bile acid transporter (ASBT/SLC10A2) and transported back to the liver through portal blood where hepatic reuptake of conjugated BAs is mediated via sodium/taurocholate cotransporting polypeptide (NTCP/SLC10A1) and organic anion transporting polypeptides (OATPs) for unconjugated BAs (not shown). In hepatocytes, farnesoid-X receptor (FXR) induces the transcriptional repressor SHP which in turn inhibits CYP7A1 (BA synthesis) and NTCP transcription (BA uptake). FXR induces BSEP, phospholipid export pump/floppase (MDR3/ABCB4; Mdr2 in mice) and cholesterol export pump (ABCG5/8). At the basolateral membrane organic solute transporter (OSTα/OSTβ), multidrug resistance-related proteine (MRP)3 and MRP4 facilitate alternative hepatic BA pump which is also in part induced by FXR (not shown). After uptake of BAs via ASBT into enterocytes (lower panel), BA-activated FXR induces sinusoidal OSTα/OSTβ heterodimer for BA efflux into portal blood. Intestinal FXR via DIET1 induces fibroblast growth factor (FGF) 19, which circulates to the liver and binds to its receptor FGFR4, subsequently inhibiting BA synthesis. Gut microbiota deconjugate and dehydroxylate primary BAs into secondary BAs. Enterohepatic drugs acting within the gut-liver axis: (non-)steroidal FXR agonists (eg, obeticholic acid) and FGF19 mimetics. Cholehepatic drugs, such as nor-ursodeoxycholic acid (norUDCA), undergo cholehepatic shunting between hepatocytes and cholangiocytes, thereby cutting short the enterohepatic circulation. Transport blockers: ASBT inhibitors and BA sequestrants as well as NTCP inhibitors, prevent intestinal or hepatic BA reuptake. TJ, tight junction.CC BY-NC · PubMed Central
Figure 3 Nuclear receptors as therapeutic targets regulating metabolism and inflammation. Hepatocyte, left panel: farnesoid X receptor (FXR) represses hepatic bile acid (BA) uptake sodium/taurocholate cotransporting polypeptide (NTCP) and BA synthesis cytochrome P450 7A1 (CYP7A1) via induction of the transcriptional repressor SHP (not shown). Moreover intestine‐derived fibroblast growth factor (FGF) 19 (binding to the FGFR4/βKlotho dimer) also downregulates CYP7A1 expression. Conversely, FXR promotes biliary excretion of BAs, phospholipids (PL) and bilirubin via induction of canalicular bile salt export pump (BSEP), multidrug resistant protein 3 (MDR3) and multidrug resistance-related protein 2 (MRP2), respectively (centre), and also facilitates BA elimination via alternative basolateral BA transporter such as organic solute transporter (OSTα/β) (not shown). BA detoxification by phase 1 and 2 enzymes is stimulated through FXR and peroxisome proliferator-activated receptor (PPAR)α. PPARα stimulates phospholipid secretion (via MDR3), thus counteracting intrinsic bile toxicity. Right panel: FXR as well as PPAR α and δ reduce inflammation via suppression of NFκΒ. FXR and PPARγ improve hepatic insulin sensitivity. FGF19, FGF21, FXR and thyroid hormone receptor beta (THRβ) suppress de novo lipogenesis, while PPAR α and δ stimulate β−oxidation. In cholangiocytes (lower panel), activation of FXR, vitamin D receptor (VDR) and glucocorticoid receptor (GR) exert cholangioprotective effects via upregulation of vasoactive intestinal polypeptide receptor 1 (VPAC1), anion exchanger (AE) 2 and cathelicidin. Activation of PPARγ in cholangiocytes reduces vascular cell adhesion molecule (VCAM‐1) expression, thereby counteracting reactive cholangiocyte phenotype. Anti-fibrotic effects of nuclear receptors (NRs) in hepatic stellate cells (HSCs, far right panel): PPARα and γ and VDR reduce expression of profibrogenic genes such as alpha smooth muscle actin (αSMA), Collagen 1a1 (Col1α1), TIMP1, platelet-derived growth factor (PDGF), transforming growth factor beta (TGFβ) and angiopoietin-2 (ANG2). Furthermore, NRs reduce migration, proliferation as well as trans-differentiation of HSC into myofibroblasts. Anti-inflammatory effects of NRs are related to their activation in immune cells such as macrophages and Kupffer cells (as well as adaptive immune cells, not shown). Activation of FGF21, PPARα, γ, δ and VDR reduce expression of proinflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin 1 beta (IL1β) (lower right panel). Cenicriviroc (CVC) an antagonist for C-C chemokine receptor type 2 and 5 (CCR2/5) on macrophages, Kupffer cells and HSCs exerts anti-inflammatory and anti-fibrotic effects, As result of FGF21 and PPARγ activation in adipocytes, insulin sensitivity is increased (lower left panel).
Figure 3 Nuclear receptors as therapeutic targets regulating metabolism and inflammation. Hepatocyte, left panel: farnesoid X receptor (FXR) represses hepatic bile acid (BA) uptake sodium/taurocholate cotransporting polypeptide (NTCP) and BA synthesis cytochrome P450 7A1 (CYP7A1) via induction of the transcriptional repressor SHP (not shown). Moreover intestine‐derived fibroblast growth factor (FGF) 19 (binding to the FGFR4/βKlotho dimer) also downregulates CYP7A1 expression. Conversely, FXR promotes biliary excretion of BAs, phospholipids (PL) and bilirubin via induction of canalicular bile salt export pump (BSEP), multidrug resistant protein 3 (MDR3) and multidrug resistance-related protein 2 (MRP2), respectively (centre), and also facilitates BA elimination via alternative basolateral BA transporter such as organic solute transporter (OSTα/β) (not shown). BA detoxification by phase 1 and 2 enzymes is stimulated through FXR and peroxisome proliferator-activated receptor (PPAR)α. PPARα stimulates phospholipid secretion (via MDR3), thus counteracting intrinsic bile toxicity. Right panel: FXR as well as PPAR α and δ reduce inflammation via suppression of NFκΒ. FXR and PPARγ improve hepatic insulin sensitivity. FGF19, FGF21, FXR and thyroid hormone receptor beta (THRβ) suppress de novo lipogenesis, while PPAR α and δ stimulate β−oxidation. In cholangiocytes (lower panel), activation of FXR, vitamin D receptor (VDR) and glucocorticoid receptor (GR) exert cholangioprotective effects via upregulation of vasoactive intestinal polypeptide receptor 1 (VPAC1), anion exchanger (AE) 2 and cathelicidin. Activation of PPARγ in cholangiocytes reduces vascular cell adhesion molecule (VCAM‐1) expression, thereby counteracting reactive cholangiocyte phenotype. Anti-fibrotic effects of nuclear receptors (NRs) in hepatic stellate cells (HSCs, far right panel): PPARα and γ and VDR reduce expression of profibrogenic genes such as alpha smooth muscle actin (αSMA), Collagen 1a1 (Col1α1), TIMP1, platelet-derived growth factor (PDGF), transforming growth factor beta (TGFβ) and angiopoietin-2 (ANG2). Furthermore, NRs reduce migration, proliferation as well as trans-differentiation of HSC into myofibroblasts. Anti-inflammatory effects of NRs are related to their activation in immune cells such as macrophages and Kupffer cells (as well as adaptive immune cells, not shown). Activation of FGF21, PPARα, γ, δ and VDR reduce expression of proinflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin 1 beta (IL1β) (lower right panel). Cenicriviroc (CVC) an antagonist for C-C chemokine receptor type 2 and 5 (CCR2/5) on macrophages, Kupffer cells and HSCs exerts anti-inflammatory and anti-fibrotic effects, As result of FGF21 and PPARγ activation in adipocytes, insulin sensitivity is increased (lower left panel).CC BY-NC · PubMed Central

Verification

Claims the paper makes

24 Valid · 7 Not valid · 83 Not checked · 13 Own results and interpretations

60 more claims · 11 with their cited sources checked

Create a free account to see all 127 claims and to verify the 127 references still open.

See all claims — free account
  • It may state two separate claims as one. 56
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 254 references

Research works printed but not linked: 6

  1. Kowdley, 2019, The nonsteroidal farnesoid X receptor (FXR) agonist Cilofexor improves liver biochemistry in patients with primary biliary cholangitis (pBC): a phase 2, randomized, placebo-controlled trial, Hepatology, 70, 31a
  2. Alkhouri, 2020, Safety and efficacy of combination therapies including Semaglutide, Cilofexor, and Firsocostat in patients with NASH, Hepatology, 72, 131A
  3. Lucas, 2020, Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48‐week results from part C of the phase 2 flight‐fxr study, Hepatology, 72, 101A
  4. Harrison, 2020, A 52-week multi-center double-blind randomized phase 2 study of Seladelpar, a potent and selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist, in patients with nonalcoholic steatohepatitis (NASH), Hepatology, 72, 1043A
  5. Harrison, 2020, RESOLVE-IT phase 3 of Elafibranor in NASH: final results of the week 72 interim surrogate efficacy analysis, Hepatology, 72, LP23
  6. Harrison, 2021, Efruxifermin (EFX) improved markers of fibrosis, liver injury andmetabolism in F4 NASH patients with compensated cirrhosis, J Hepatol, 75

Cited by

See all 218

Metadata

Authors
Trauner, M., & Fuchs, C. D.
Affiliations
Medical University of Vienna (AT)
Corresponding author
Trauner, Michael
Venue
Gut
Publisher
BMJ
Published
2021-10-06
Volume
71
Issue
1
Pages
194-209
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W3204219369
Cited by
204
References
254
Citations by year
2026: 38 · 2025: 42 · 2024: 44 · 2023: 48 · 2022: 32
FWCI
4.74
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Austrian Science Fund (F7310‐B21, I2755-B30)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
cholestatic liver disease, non-alcoholic fatty liver disease, nuclear receptors, farnesoid X receptor, peroxisome proliferator-activated receptors, thyroid hormone receptor beta 1, bile acid signaling, FGF19, enterohepatic circulation, liver fibrosis, liver inflammation, hepatic lipid metabolism
MeSH terms
Cholestasis, Gastrointestinal Agents, Humans, Receptors, Cytoplasmic and Nuclear, Molecular Targeted Therapy, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Novel therapeutic targets for cholestatic and fatty liver disease. https://app.cochat.ai/papers/10.1136/gutjnl-2021-324305
The paper
Trauner, M., & Fuchs, C. D. (2022). Novel therapeutic targets for cholestatic and fatty liver disease. Gut. https://doi.org/10.1136/gutjnl-2021-324305

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.